Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE
Imunologia e AlergiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The journal of allergy and clinical immunology. In practice
- Publicado em
- 14 fev 2025
- Citações
- 17
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE
Matthew Greenhawt, Deborah Albright, Sara Anvari, Nicolette Arends, Peter D Arkwright, Philippe Bégin, Katharina Blumchen, Terri Brown-Whitehorn, Heather Cassell, Edmond S Chan et al.
Descritores MeSH
- Desensitization, Immunologic
- Plant Proteins
- Allergens
- Peanut Hypersensitivity
- Antigens, Plant
- Administration, Cutaneous
- Infant
- Male
- Arachis
- Treatment Outcome
Veja também
Estudos relacionados
- Efficacy and safety of epicutaneous immunotherapy in children with peanut allergy with atopic comorbidities
- Baseline epitope-specific IgE profiles are predictive of sustained unresponsiveness or high threshold 1-year post oral immunotherapy in the POISED trial
- High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapy
- Evolution of epitope-specific IgE and IgG4 antibodies in children enrolled in the LEAP trial